HTG Molecular Diagnostics (NASDAQ:HTGM) and PositiveID (OTCMKTS:PSID) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Insider & Institutional Ownership
51.0% of HTG Molecular Diagnostics shares are owned by institutional investors. 3.9% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 48.4% of PositiveID shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for HTG Molecular Diagnostics and PositiveID, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HTG Molecular Diagnostics||0||0||4||0||3.00|
HTG Molecular Diagnostics currently has a consensus price target of $7.33, suggesting a potential upside of 183.14%. Given HTG Molecular Diagnostics’ higher possible upside, research analysts plainly believe HTG Molecular Diagnostics is more favorable than PositiveID.
Valuation & Earnings
This table compares HTG Molecular Diagnostics and PositiveID’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|HTG Molecular Diagnostics||$21.50 million||3.45||-$16.45 million||($0.60)||-4.32|
|PositiveID||$5.36 million||0.00||-$8.56 million||N/A||N/A|
PositiveID has lower revenue, but higher earnings than HTG Molecular Diagnostics.
This table compares HTG Molecular Diagnostics and PositiveID’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HTG Molecular Diagnostics||-76.52%||-64.49%||-34.45%|
Volatility and Risk
HTG Molecular Diagnostics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, PositiveID has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500.
PositiveID beats HTG Molecular Diagnostics on 6 of the 11 factors compared between the two stocks.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
PositiveID Corporation, a life sciences and technology company, develops and sells molecular diagnostic systems for bio-threat detection and medical testing in the United States and internationally. It operates through three segments: Molecular Diagnostics, Medical Devices, and Mobile Labs. The company develops microfluidic systems for the automated preparation and performance of biological assays to detect biological threats and analyze biological samples at the point of need. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. The company's microfluidic bio-agent autonomous networked detector (M-BAND) technology is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. Its M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. The company's FireflyDX is an automated pathogen detection system for rapid diagnostics for clinical and point-of-need applications. Its FireflyDX system detects and identifies common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, methicillin-susceptible staphylococcus aureus, clostridium difficile, Zika virus, Ebola virus, influenza, and others. In addition, PositiveID Corporation markets Caregiver, a non-contact clinical thermometer that measures forehead temperature in adults, children, and infants for hospitals, physicians' offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals; and manufactures and sells specialty technology vehicles for mobile laboratory, command and communications applications, and mobile cellular systems. The company was formerly known as VeriChip Corporation and changed its name to PositiveID Corporation in November 2009. PositiveID Corporation was founded in 2001 and is headquartered in Delray Beach, Florida.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.